Synovial Sarcoma Drug Pipeline Analysis Report 2025
Description
Synovial sarcoma accounts for nearly 10% of all soft tissue tumors. With 800-1000 individuals undergoing a diagnosis for the condition each year, it has an incidence rate of 0.177 per 100,000 people in the United States. As a result, several healthcare and pharmaceutical companies are involved in developing effective synovial sarcoma therapeutics to treat and manage the disease efficiently.
Report Coverage
The Synovial Sarcoma Drug Pipeline Report by Expert Market Research gives comprehensive insights into synovial sarcoma therapeutic drugs currently undergoing clinical trials for synovial sarcoma treatment. It covers various aspects related to the details of each of these drugs under development. The synovial sarcoma report assessment includes an analysis of over 100 pipeline drugs and 50+ companies . It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on synovial sarcoma.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing synovial sarcoma pipeline development activities are covered in the report.
Synovial Sarcoma Drug Pipeline Outlook
Synovial sarcoma is a rare cancer that primarily affects muscles or ligaments, including arms, legs, knees or feet. The symptoms for this condition may vary based on tumor location or form. It is commonly diagnosed through X-ray, CT scan, ultrasound, or biopsy.
In August 2024, the United States FDA approved Adaptimmune's Tecelra (afamitresgene autoleucel) for treating unresectable or metastatic synovial sarcoma. It is a gene therapy for adults who have received prior chemotherapy. The approval was granted on the basis of an open-label clinical trial that involved 44 patients. The overall response rate (ORR) was 43.2%. With synovial sarcoma emerging drugs belonging to various drug classes getting approvals from vital regulatory authorities, the drug pipeline for synovial sarcoma is promising.
Synovial Sarcoma – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of synovial sarcoma drug candidates based on various segmentations such as:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
EMR’s synovial sarcoma therapeutic assessment report covers 50+ drug analyses based on drug classes:
EMR’s synovial sarcoma clinical assessment covers 50+ drug analyses based on the route of administration.
The synovial sarcoma report insight covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total clinical trials conducted, with over 60 drugs in the pipeline.
Synovial Sarcoma – Pipeline Assessment Segmentation, By Drug Class
The drug class categories covered under synovial sarcoma pipeline analysis include chemotherapy agents, targeted therapies and immunotherapies, among others. Immunotherapy can be further categorised into immune checkpoint inhibitors as well as T-cell therapies. Each drug class has a different mode of action, and it is recommended based on disease prognosis. Chemotherapy drugs work by killing tumor cells while targeted therapy drugs interfere with particular molecular targets and inhibit further cell growth.
The synovial sarcoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials.
Synovial Sarcoma Clinical Trials Assessment – Competitive Dynamics
The EMR report for the synovial sarcoma drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in synovial sarcoma pipeline landscape:
Synovial Sarcoma – Emerging Drugs Profile
Ramucirumab (LY3009806)
Sponsored by Eli Lilly and Company, ramucirumab (in combination with chemotherapy) is being investigated to treat recurrent, refractory, or relapsed pediatric synovial sarcoma. As a part of the CAMPFIRE master protocol, the synovial-sarcoma drug candidate is being evaluated in a randomized open-label Phase 1/2 study.
FHD-609
The drug is under evaluation for treating advanced synovial sarcoma or advanced SMARCB1-loss tumors. Sponsored by Foghorn Therapeutics Inc., FHD-609 is administered intravenously twice a week. The Phase 1 study entails around 104 patients, enrolled for dose escalation and expansion.
CFT8634
As a part of an open-label non-randomized, first-in-human Phase 1/2 study, this synovial-sarcoma therapeutic drug is under investigation to treat synovial sarcoma. It is sponsored by C4 Therapeutics Inc. and assesses antitumor activity along with pharmacokinetics and pharmacodynamics.
Radiolabeled OTSA101-DTPA
Developed by OncoTherapy Science, Inc., this anti-frizzled homolog 10 monoclonal antibody, is being evaluated for its safety and pharmacokinetics against relapsed or refractory synovial sarcoma.
Reasons To Buy This Report
The Synovial Sarcoma Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for synovial sarcoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into synovial sarcoma collaborations, market trends, regulatory environments, and potential growth opportunities.
Key Questions Answered in the Synovial Sarcoma – Pipeline Assessment Report
Synovial Sarcoma Market
Clinical Trials Market
Pharmaceuticals Market
Report Coverage
The Synovial Sarcoma Drug Pipeline Report by Expert Market Research gives comprehensive insights into synovial sarcoma therapeutic drugs currently undergoing clinical trials for synovial sarcoma treatment. It covers various aspects related to the details of each of these drugs under development. The synovial sarcoma report assessment includes an analysis of over 100 pipeline drugs and 50+ companies . It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on synovial sarcoma.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing synovial sarcoma pipeline development activities are covered in the report.
Synovial Sarcoma Drug Pipeline Outlook
Synovial sarcoma is a rare cancer that primarily affects muscles or ligaments, including arms, legs, knees or feet. The symptoms for this condition may vary based on tumor location or form. It is commonly diagnosed through X-ray, CT scan, ultrasound, or biopsy.
In August 2024, the United States FDA approved Adaptimmune's Tecelra (afamitresgene autoleucel) for treating unresectable or metastatic synovial sarcoma. It is a gene therapy for adults who have received prior chemotherapy. The approval was granted on the basis of an open-label clinical trial that involved 44 patients. The overall response rate (ORR) was 43.2%. With synovial sarcoma emerging drugs belonging to various drug classes getting approvals from vital regulatory authorities, the drug pipeline for synovial sarcoma is promising.
Synovial Sarcoma – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of synovial sarcoma drug candidates based on various segmentations such as:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
EMR’s synovial sarcoma therapeutic assessment report covers 50+ drug analyses based on drug classes:
- Chemotherapy Agent
- Targeted Therapy
- Immunotherapy
EMR’s synovial sarcoma clinical assessment covers 50+ drug analyses based on the route of administration.
- Oral
- Parenteral
- Others
The synovial sarcoma report insight covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total clinical trials conducted, with over 60 drugs in the pipeline.
Synovial Sarcoma – Pipeline Assessment Segmentation, By Drug Class
The drug class categories covered under synovial sarcoma pipeline analysis include chemotherapy agents, targeted therapies and immunotherapies, among others. Immunotherapy can be further categorised into immune checkpoint inhibitors as well as T-cell therapies. Each drug class has a different mode of action, and it is recommended based on disease prognosis. Chemotherapy drugs work by killing tumor cells while targeted therapy drugs interfere with particular molecular targets and inhibit further cell growth.
The synovial sarcoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials.
Synovial Sarcoma Clinical Trials Assessment – Competitive Dynamics
The EMR report for the synovial sarcoma drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in synovial sarcoma pipeline landscape:
Synovial Sarcoma – Emerging Drugs Profile
Ramucirumab (LY3009806)
Sponsored by Eli Lilly and Company, ramucirumab (in combination with chemotherapy) is being investigated to treat recurrent, refractory, or relapsed pediatric synovial sarcoma. As a part of the CAMPFIRE master protocol, the synovial-sarcoma drug candidate is being evaluated in a randomized open-label Phase 1/2 study.
FHD-609
The drug is under evaluation for treating advanced synovial sarcoma or advanced SMARCB1-loss tumors. Sponsored by Foghorn Therapeutics Inc., FHD-609 is administered intravenously twice a week. The Phase 1 study entails around 104 patients, enrolled for dose escalation and expansion.
CFT8634
As a part of an open-label non-randomized, first-in-human Phase 1/2 study, this synovial-sarcoma therapeutic drug is under investigation to treat synovial sarcoma. It is sponsored by C4 Therapeutics Inc. and assesses antitumor activity along with pharmacokinetics and pharmacodynamics.
Radiolabeled OTSA101-DTPA
Developed by OncoTherapy Science, Inc., this anti-frizzled homolog 10 monoclonal antibody, is being evaluated for its safety and pharmacokinetics against relapsed or refractory synovial sarcoma.
Reasons To Buy This Report
The Synovial Sarcoma Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for synovial sarcoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into synovial sarcoma collaborations, market trends, regulatory environments, and potential growth opportunities.
Key Questions Answered in the Synovial Sarcoma – Pipeline Assessment Report
- What is the current landscape of synovial sarcoma pipeline drugs?
- Which companies/institutions are developing synovial sarcoma emerging drugs?
- How many phase II drugs are currently present in synovial sarcoma pipeline drugs?
- Which company is leading the synovial sarcoma pipeline development activities?
- What is the current synovial sarcoma therapeutic assessment?
- What are the opportunities and challenges present in the synovial sarcoma drug pipeline landscape?
- What is the efficacy and safety profile of synovial sarcoma pipeline drugs?
- Which companies/institutions are involved in synovial sarcoma collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in synovial sarcoma?
Synovial Sarcoma Market
Clinical Trials Market
Pharmaceuticals Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology and Assumptions
- 2 Executive Summary
- 3 Overview of Synovial Sarcoma
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Synovial Sarcoma: Epidemiology Snapshot
- 5.1 Synovial Sarcoma Incidence by Key Markets
- 5.2 Synovial Sarcoma– Patients Seeking Treatment in Key Markets
- 6 Synovial Sarcoma: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Synovial Sarcoma: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Synovial Sarcoma, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Synovial Sarcoma Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Synovial Sarcoma Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 LV305
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Drug 2
- 10.2.3 Other Drugs
- 11 Synovial Sarcoma Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Ramucirumab
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Other Drugs
- 12 Synovial Sarcoma Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 CFT8634
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 OTSA101-DTPA-90Y
- 12.2.3 FHD-609
- 12.2.4 Other Drugs
- 13 Synovial Sarcoma Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Synovial Sarcoma, Key Drug Pipeline Com panies
- 14.1 Adaptimmune
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Eli Lilly and Company
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Takara Bio Inc.
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Foghorn Therapeutics Inc.
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 OncoTherapy Science, Inc.
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 GlaxoSmithKline
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 14.8 Epizyme, Inc.
- 14.8.1 Company Snapshot
- 14.8.2 Pipeline Product Portfolio
- 14.8.3 Financial Analysis
- 14.8.4 Recent News and Developments
- 14.9 C4 Therapeutics, Inc.
- 14.9.1 Company Snapshot
- 14.9.2 Pipeline Product Portfolio
- 14.9.3 Financial Analysis
- 14.9.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
